How Routine Pharmacovigilance Failed to Identify Finasteride’s Persistent Sexual Side Effects

    October 2021 in “ International Journal of Andrology ”
    Michael S. Irwig
    Image of study
    TLDR Finasteride, a hair loss drug, has unaddressed sexual side effects due to the manufacturer's inadequate safety measures and lack of additional studies.
    The document discusses the controversy surrounding the persistent sexual side effects of finasteride, a drug used for androgenetic alopecia. Despite warnings from regulatory agencies and published articles on the adverse effects, the existence of post-finasteride syndrome remains disputed. In 2021, internal documents from Merck, the manufacturer of finasteride, revealed that the company had identified potential risks such as persistent erectile dysfunction, male infertility, and depressive disorders. However, instead of conducting further studies to investigate these risks, Merck's Risk Management Safety Team opted for routine pharmacovigilance. The document criticizes this decision, arguing that it failed to provide adequate information on the drug's side effects. The document also criticizes the FDA for not advising or requiring Merck to conduct additional safety studies. As of June 2021, the FDA's Adverse Event Reporting System recorded 10,295 serious adverse events for finasteride, with the most common reactions related to sexual dysfunction.
    Discuss this study in the Community →

    Research cited in this study

    6 / 6 results

    Related Community Posts Join

    6 / 1000+ results

      community Why is everyone not directly advised Dutasteride?

      in Finasteride/Dutasteride  165 upvotes 1 month ago
      Dutasteride is less commonly prescribed for hair loss because it is not FDA-approved for this purpose, unlike finasteride, which is more accessible and preferred due to fewer side effects. Dutasteride may be more effective in reducing DHT but has a longer half-life and potentially more significant side effects.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  136 upvotes 7 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community When are we getting a cure to hair loss?

      in Chat 1 year ago
      Potential treatments for hair loss, including Minoxidil, finasteride, RU58841 and various upcoming pharmaceuticals, gene editing and cloning. It is suggested that a cure, if found, would be highly profitable due to the large number of people affected by hair loss globally.

      community A Different Take on Curing MBP

       16 upvotes 5 years ago
      Addressing hair loss by focusing on posture, blood flow, and craniofacial development. Methods include improving posture, cardiovascular activity, scalp massages, healthy diet, meditation, using minoxidil, and addressing craniofacial issues.

    Related Research

    8 / 8 results